Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015
Jamjoom Pharmaceuticals Factory — FY2025 Earnings Presentation
22 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, Feb 24, 2026
Slide 1: Earnings Presentation FY 2025
Earnings Presentation FY 2025 Jeddah | 24 February 2026
Slide 2: Business and Strategy Highlights
Business and Strategy Highlights Tarek Hosni, CEO
Slide 3: Disclaimer
3 Disclaimer This presentation has been prepared solely for use as an investor presentation for Jamjoom Pharmaceuticals Factory Company (the “Company”). By attending or by reading this presentation, you agree to be bound by the following limitations. The information contained in this presentation is
Slide 4: FY 2025 Highlights: Consistent delivery of revenue and profitability
4 Business and Strategy Highlights FY 2025 Highlights: Consistent delivery of revenue and profitability Revenue # of Brands +3 in Consumer Health Underpinned by successful execution of our +1 in Anti-Diabetic FY 25 +14% YoY market penetration strategy across key FY 25 +6 YTD +1 in Ophthalmology SAR
Slide 5: From foundation to acceleration, 2021 revenue more than doubled
5 Business and Strategy Highlights From foundation to acceleration, 2021 revenue more than doubled 1,501 1,318 1,101 917 736 2021 2022 2023 2024 2025 Jamjoom Earnings Presentation - 24/02/2026
Slide 6: Fast-growing business, even faster-growing margins
6 Business and Strategy Highlights Fast-growing business, even faster-growing margins EBITDA Growth Net Profit Growth 464 533 437 357 344 292 260 215 171 171 29.2% 28.3% 31.3% 33.2% 35.5% 23.2% 18.7% 26.6% 27.0% 30.9% 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 Jamjoom Earnings Presentation -
Slide 7: 2025: Market Share Gains, Portfolio Expansion, and Operational Scale-Up
7 Business and Strategy Highlights 2025: Market Share Gains, Portfolio Expansion, and Operational Scale-Up •JP ranked 2nd in the Retail Market1 (4th in 2024) with 6.3% Market Share (+14%) Saudi Market •JP ranked 4th in the Total Market2 (7th in 2024) with 4.5% Market Share (+18%) •Iraq (+12.6%) and
Slide 8: Optimizing to Scale Production Across Facilities
8 Business and Strategy Highlights Optimizing to Scale Production Across Facilities Jeddah Jeddah Cairo Algiers* Main Facility Sterile Facility Main Facility Facility 149m 20m 52m 15m Production Capacity p.a. Production Capacity p.a. Production Capacity p.a. Production Capacity p.a. (OSD Line) 129m
Slide 9: Consistent Growth Across Core TAs and Markets
9 Business and Strategy Highlights Consistent Growth Across Core TAs and Markets Revenue Contribution by Therapeutic Area, YoY (SARmn) Revenue Contribution by Country, YoY (SARmn) +14% +14% 131 19 15 14 4 1,501 14 7 7 3 1,501 1,318 38 11 57 30 16 1,318 Institutional sales Solid recovery to healthy E
Slide 10: Monthly revenue growth for top KSA pharma for the past 4 years
10 Business and Strategy Highlights Monthly revenue growth1 for top 5 KSA pharma for the past 4 years Peer 1 21 negative months Peer 2 8 negative months 2 negative months Peer 3 17 negative months Peer 4 21 negative months Jan-22 Jul-22 Jan-23 Jul-23 Jan-24 Jul-24 Jan-25 Jul-25 Dec-25 IQVIA Data1 20
Slide 11: Portfolio Transformation: From Niche Specialty to Diversified, High-Value TAs
11 Business and Strategy Highlights Portfolio Transformation: From Niche Specialty to Diversified, High-Value TAs 2021 Revenue Contribution by Therapeutic Area (SARmn) 2025 Revenue Contribution by Therapeutic Area (SARmn) Anti-diabetic Pain & Inflammation C. Nervous System Pain & Inflammation 2% 5%
Slide 12: Strong Execution Across Portfolio: SFDA Registrations, 6 Launches, and a 57-Product Pipeline
12 Business and Strategy Highlights Strong Execution Across Portfolio: 7 SFDA Registrations, 6 Launches, and a 57-Product Development Pipeline Under SFDA review Ready for SFDA Submission Under Development Total 4 Ophthalmology 9 15 2 1 General Medicine 1 Revenue growth EBITDA Dermatology margin 2 4
Slide 13: Delivering on BD Strategy: 16 Agreements Signed Across High-Value TAs
13 Business and Strategy Highlights Delivering on BD Strategy: 16 Agreements Signed Across High-Value TAs Selected key agreements signed No. Partner Product Type Therapeutic Area Coverage Model 1. EU/Japanese-Based Generic GIT MENA License and supply with potential localization 2. Italian-Based Gene
Slide 14: 2026 & Beyond: JP Strategic Potential Initiatives
14 Business and Strategy Highlights 2026 & Beyond: JP Strategic Potential Initiatives JV with PIF (Lifera) Localization of Vaccines and Biologicals Exploring potential alliances/acquisitions to accommodate future Manufacturing Expansion capacity growth Exploring opportunities for In-Licensing & Stra
Slide 15: Financial Highlights
Financial Highlights Anwer Mohiuddin, CFO
Slide 16: Q4 Delivering Strong Revenue Growth & Margins
16 Financial Highlights Q4 Delivering Strong Revenue Growth & Margins Revenue (SARmn) EBITDA (SARmn) +17% +22% 305 88 260 72 27.7% 28.8% EBITDA Margin 4Q 24 4Q 25 4Q 24 4Q 25 Gross Profit (SARmn) Net Profit (SARmn) +18% +32% 187 159 68 52 Driven by high gross margin coupled with improved operating l
Slide 17: Operational Discipline to Curtail Rising Costs
17 Financial Highlights Operational Discipline to Curtail Rising Costs … Total Cost Of Revenue Movement YoY (SARmn) Operating Expenses Movement YoY (SARmn) +13% 6 9 562 14 36 +13% 498 41 8 474 422 5 Through targeted, high-impact spending and controlled cost discipline, JP absorbed inflation and empl
Slide 18: and Continue Healthy Delivery of Expanding Profitability
18 Financial Highlights … and Continue Healthy Delivery of Expanding Profitability EBITDA Movement YoY (SARmn) +22% 182 EBITDA Margin 35.5% 25 533 EBITDA Margin (64) 33.2% (41) (8) 437 Net other income and normalized ECL provisions offset by OPEX increase and lower share of profit from Algeria +14%
Slide 19: Scaling Working Capital to Support Growth Initiatives
19 Financial Highlights Scaling Working Capital to Support Growth Initiatives ▪ The cash conversion cycle (CCC) increased to 256 days (+8% YoY), driven primarily by Cash Conversion Cycle (Days) the shift toward institutional sales and shorter supplier terms. This working-capital investment supports
Slide 20: Outlook and Guidance
Jamjoom Pharma LojLé pgaa Outlook and Guidance
Slide 21: Financial Guidance: FY25 Achieved and Guiding for Positive Growth Beyond
21 Outlook and Guidance Financial Guidance: FY25 Achieved and Guiding for Positive Growth Beyond FY 25 Guidance FY 25 Actual Results FY 26-27 Guidance Revenue growth 12-15% 13.8% 10-12% (CAGR) EBITDA margin 34-34.5% 35.5% 33-35% CAPEX 4-6% 5.0% 6-9% 50-60% payout subject to Dividend 50-60% payout 60
Slide 22: Q&A
Q&A Tarek Hosni, Chief Executive Officer Anwer Mohiuddin, Chief Financial Officer Muhammad Bin Khalid, Assoc. Director – Finance & IR
Jamjoom Pharmaceuticals Factory — FY2025 Earnings Presentation on 6ix